YU49287B - Soli derivata indola - Google Patents

Soli derivata indola

Info

Publication number
YU49287B
YU49287B YU56995A YU56995A YU49287B YU 49287 B YU49287 B YU 49287B YU 56995 A YU56995 A YU 56995A YU 56995 A YU56995 A YU 56995A YU 49287 B YU49287 B YU 49287B
Authority
YU
Yugoslavia
Prior art keywords
indole
salt derivatives
compound
infra
twelve
Prior art date
Application number
YU56995A
Other languages
English (en)
Other versions
YU56995A (sh
Inventor
Valerie Denise Harding
Ross James Macrae
Ronald James Ogilvie
Original Assignee
Pfizer Research And Development Company N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10760474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU49287(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Research And Development Company N.V./S.A. filed Critical Pfizer Research And Development Company N.V./S.A.
Publication of YU56995A publication Critical patent/YU56995A/sh
Publication of YU49287B publication Critical patent/YU49287B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)

Abstract

Jedinjenje formule (I): Kristalni, α-polimorfni oblik jedinjenja prema zahtevu 1, naznačen time, što ga karakteriše infra-crveni spektar koji pokazuje značajne apsorpcione trake ν=3371, 3293, 2713, 2524, 1419, 1343, 1307, 1264, 1151, 1086, 1020, 1008, 999, 922, 900, 805, 758, 740, 728, 689, 672, 652, 640, 598, 581, 573, 531, 498, 465, 457, 443, 428, 422, 414 i 399 cm-1. Prijava sadrži još tri nezavisna i dvanaest zavisnih patentnih zahteva.
YU56995A 1994-08-27 1995-08-25 Soli derivata indola YU49287B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9417310A GB9417310D0 (en) 1994-08-27 1994-08-27 Therapeutic agents

Publications (2)

Publication Number Publication Date
YU56995A YU56995A (sh) 1998-07-10
YU49287B true YU49287B (sh) 2005-03-15

Family

ID=10760474

Family Applications (1)

Application Number Title Priority Date Filing Date
YU56995A YU49287B (sh) 1994-08-27 1995-08-25 Soli derivata indola

Country Status (45)

Country Link
US (2) US6110940A (sh)
EP (1) EP0776323B1 (sh)
JP (1) JP2904588B2 (sh)
KR (1) KR100228952B1 (sh)
CN (1) CN1066727C (sh)
AP (1) AP576A (sh)
AT (1) ATE163182T1 (sh)
AU (1) AU691005B2 (sh)
BG (1) BG61840B1 (sh)
BR (1) BRPI9503812B1 (sh)
CA (1) CA2198599C (sh)
CO (1) CO4410334A1 (sh)
CZ (1) CZ287693B6 (sh)
DE (1) DE69501620T2 (sh)
DK (1) DK0776323T3 (sh)
DZ (1) DZ1923A1 (sh)
EG (1) EG23822A (sh)
ES (1) ES2112650T3 (sh)
FI (1) FI113768B (sh)
GB (1) GB9417310D0 (sh)
GR (1) GR3026475T3 (sh)
HR (1) HRP950460B1 (sh)
HU (1) HU227822B1 (sh)
IL (1) IL115013A (sh)
IS (1) IS1850B (sh)
LV (1) LV11800B (sh)
MA (1) MA23650A1 (sh)
MX (1) MX9701538A (sh)
MY (1) MY113733A (sh)
NO (1) NO311297B1 (sh)
NZ (1) NZ288210A (sh)
OA (1) OA10600A (sh)
PE (1) PE41596A1 (sh)
PL (1) PL180867B1 (sh)
RO (1) RO116400B1 (sh)
RU (1) RU2159241C2 (sh)
SA (1) SA95160156B1 (sh)
SI (1) SI9520091B (sh)
SK (1) SK282922B6 (sh)
TN (1) TNSN95092A1 (sh)
TR (1) TR199501061A2 (sh)
UA (1) UA45980C2 (sh)
WO (1) WO1996006842A1 (sh)
YU (1) YU49287B (sh)
ZA (1) ZA957142B (sh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
ATE206921T1 (de) * 1997-07-03 2001-11-15 Pfizer Eletriptanhemisulfat und kaffein enthaltende pharmazeutische zusammenstellungen
GB9714081D0 (en) * 1997-07-03 1997-09-10 Pfizer Ltd Pharmaceutical compositions
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US20030166704A1 (en) * 2000-12-20 2003-09-04 Pfizer Inc. New process
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
MXPA05010070A (es) 2003-04-11 2005-11-23 Pfizer Combinacion farmaceutica.
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
NZ561375A (en) * 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
CA2666149A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
US20080287519A1 (en) * 2007-05-01 2008-11-20 Marioara Mendelovici Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
US20080319205A1 (en) * 2007-05-29 2008-12-25 Roman Bednar Process for preparing 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole
US20100285075A1 (en) * 2007-12-17 2010-11-11 Actavis Group Ptc Ehf Novel Hemioxalate Salt of Eletriptan
WO2009142771A2 (en) * 2008-05-22 2009-11-26 Plus Chemicals, S.A. Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan
US8349900B2 (en) * 2008-08-07 2013-01-08 Valeant International Bermuda Bupropion hydrobromide polymorphs
WO2010097703A1 (en) * 2009-02-25 2010-09-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
WO2017125351A1 (en) 2016-01-21 2017-07-27 Laboratorios Lesvi Sl Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
HUT64326A (en) * 1990-10-15 1993-12-28 Pfizer Process for production indole derivatives and pharmaceutical preparations containing these compounds
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
KR0184911B1 (ko) * 1991-11-25 1999-05-01 알렌 제이. 스피겔 인돌유도체
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (sh) * 1992-03-05 1996-10-11 Pfizer
JP2644088B2 (ja) * 1992-04-07 1997-08-25 フアイザー・インコーポレイテツド ５−ｈｔ１作動薬としてのインドール誘導体
NZ251047A (en) * 1992-04-10 1996-09-25 Pfizer Acylaminoindole derivatives and medicaments
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
PL311204A1 (en) * 1993-04-22 1996-02-05 Pfizer Res & Dev Indole derivatives as antagonists of 5-ht-like receptors for use in hemicrania
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
AU686654B2 (en) * 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives

Also Published As

Publication number Publication date
DE69501620D1 (de) 1998-03-19
SK24897A3 (en) 1998-08-05
SA95160156B1 (ar) 2005-05-30
DE69501620T2 (de) 1998-07-02
YU56995A (sh) 1998-07-10
AP576A (en) 1997-03-20
OA10600A (en) 2000-04-06
MY113733A (en) 2002-05-31
AU2735295A (en) 1996-03-22
EP0776323B1 (en) 1998-02-11
BR9503812A (pt) 1996-04-16
DK0776323T3 (da) 1998-03-30
CA2198599C (en) 2000-06-06
GB9417310D0 (en) 1994-10-19
CN1155886A (zh) 1997-07-30
KR970705557A (ko) 1997-10-09
CA2198599A1 (en) 1996-03-07
PL180867B1 (pl) 2001-04-30
IS1850B (is) 2003-02-07
US6110940A (en) 2000-08-29
SI9520091A (sl) 1998-02-28
HU227822B1 (en) 2012-03-28
PE41596A1 (es) 1996-10-12
SK282922B6 (sk) 2003-01-09
SI9520091B (sl) 2004-10-31
LV11800B (en) 1997-10-20
BG61840B1 (bg) 1998-07-31
NZ288210A (en) 1998-01-26
RO116400B1 (ro) 2001-01-30
JP2904588B2 (ja) 1999-06-14
HUT77310A (hu) 1998-03-30
IL115013A0 (en) 1995-12-08
RU2159241C2 (ru) 2000-11-20
EG23822A (en) 2007-09-19
IL115013A (en) 2000-11-21
ES2112650T3 (es) 1998-04-01
ATE163182T1 (de) 1998-02-15
DZ1923A1 (fr) 2002-02-17
CZ287693B6 (en) 2001-01-17
MX9701538A (es) 1997-05-31
TNSN95092A1 (fr) 1996-02-06
FI970800A0 (fi) 1997-02-26
US6380226B1 (en) 2002-04-30
NO970861D0 (no) 1997-02-26
WO1996006842A1 (en) 1996-03-07
EP0776323A1 (en) 1997-06-04
FI113768B (fi) 2004-06-15
NO970861L (no) 1997-02-26
GR3026475T3 (en) 1998-06-30
HRP950460A2 (en) 1997-08-31
HRP950460B1 (en) 2000-02-29
JPH09512283A (ja) 1997-12-09
CO4410334A1 (es) 1997-01-09
CZ56397A3 (cs) 1998-05-13
TR199501061A2 (tr) 1996-06-21
AP9500754A0 (en) 1995-07-31
UA45980C2 (uk) 2002-05-15
NO311297B1 (no) 2001-11-12
FI970800A (fi) 1997-02-26
BRPI9503812B1 (pt) 2017-04-18
IS4401A (is) 1996-12-19
PL318319A1 (en) 1997-06-09
MA23650A1 (fr) 1996-04-01
LV11800A (lv) 1997-06-20
AU691005B2 (en) 1998-05-07
KR100228952B1 (ko) 1999-11-01
BG101250A (en) 1997-09-30
CN1066727C (zh) 2001-06-06
ZA957142B (en) 1997-02-25

Similar Documents

Publication Publication Date Title
YU49287B (sh) Soli derivata indola
NO972922L (no) Preparater og metoder for å redusere hudirritasjon
GR3023040T3 (en) Substituted indoles as anti-aids pharmaceuticals
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
DE69725171D1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
NO20006221L (no) Fremgangsmåte for bekjempelse av skadedyr
YU25497A (sh) Postupak za dobijanje sildenafila
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
MX9700564A (es) Derivados de benzoilo y sintesis de los mismos.
KR950700308A (ko) 할리콘드린 및 관련 화합물
ES2132415T3 (es) Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol.
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
ES2144885T3 (es) Empleo como un fungicida de derivados de acido beta-amino-propionico.
RU94022277A (ru) Новые 19-норстероиды, имеющие в положении 11 - бета феноксиалкилсульфонамидную или феноксиалкилсульфонилкарбамидную цепь, метод и промежуточные продукты их получения, и содержащая их фармацевтическая композиция
ES2179254T3 (es) 1-poliarilpirazoles plaguicidas.
IE780922L (en) 1,3,5-s-HEXAHYDROSUBSTITUTED TRIAZINES
IL111966A0 (en) 4-Benzoylisoxazole derivatives, their preparation and herbicidal compositions containing them
TW327166B (en) Fluoromethoxy- or difluromethoxy-o-tolyl-acrylic acid derivatives
BG101535A (en) 1,4-diaryl-2-fluoro-2-butene insecticide and acaricidal formulations
MX9603348A (es) Derivados de disulfuro de amida indano-2-mercaptoacetilica novedosos utiles como inhibidores de encefalinasa.
RU94035685A (ru) Производные арилоксибензола, гербицидная композиция, способ борьбы с сорняками
DE69703115D1 (de) Zwischenprodukte um 2-imidazolin-5onederivate herzustellen.
MX9706283A (es) Nuevos antibioticos de polieno, 3874 hi a h6, procedimientos para su preparacion y empleo.
EA200000681A1 (ru) Фунгицидная смесь на базе амидных соединений и производных пиридина
MX9701764A (es) Derivados de imidoacidos.